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ABSTRACT OF DISSERTATION 
 
Title: Classification of breast cancer cell lines into subtypes based on genetic profile 
Abstract:  Today we know that there are several different types of breast cancer. 
Accurate identification breast cancer subtype is extremely important in treating this 
disease effectively. Consequently the process of invtro development of drugs to treat 
this disease should be naturally subtype specific.  Until now several studies have 
identified multiple breast cancer cell lines and these cell lines have served as 
invaluable invitro tumor models. However very few of these cell lines are classified 
as per their subtypes. In this thesis an effort is made to classify 59 of such breast 
cancer cell lines using genetic profile comparison approach. This approach is based 
on comparing characteristic features such as copy number and gene expression of a 
given cell line to those observed from the tissue samples of different breast subtypes.  
The tissue data for this comparison comes from The Cancer Genome Atlas (TCGA) 
while cell line data is taken from Cancer Cell Line Encyclopedia (CCLE).   
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CHAPTER ONE 
 INTODUCTION 
1.1 Breast Cancer 
Cancer of cells of the breast is known as breast cancer. It is a condition characterized 
by uncontrolled growth of cells in breast tissue, which may lead in formation of a 
lump in breast. Actually breast cancer is a complex disease, in fact each of its subtype 
has its own clinical and pathological characteristic. Cancer originating from the 
lobules is called as lobular carcinoma, while cancer resulting from the ductal cells of 
breast is called as ductal carcinoma. Once the cancer spreads from its origin to other 
tissues it is termed as invasive carcinoma. Normally cancer limits to the tissue of 
origin and known as non-invasive form of carcinoma. Both ductal and lobular cancer 
can metastasize or spread to other parts of the body and may turn into invasive 
carcinomas. Invasive ductal carcinoma constitutes 80% of total invasive cancers 
while Invasive lobular carcinoma occurs around 10% to 15% of times. Other breast 
cancer types which are uncommon include inflammatory breast cancer, Phyllodes 
breast cancer, Paget disease of the nipple[1]. 
The risk of breast cancer is high among women and is one of the major cause of death, 
next to lung cancer [1]. In the US chances are that every one out of eight women will 
suffer from breast cancer [1] . In 2015 nearly 0.23 million new cases of breast cancer 
in women will be reported and around 40,000 women will lose their life to breast 
cancer [1]. According to American Cancer Society, the majority i.e. more than half of 
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the breast cancer cases belong to invasive ductal carcinoma, while breast cancer 
remains the most common condition affecting women [1]. Although breast cancer 
majorly occurs in females but there are rare cases of breast cancer in men. American 
Cancer Society states that there will be around 2000 new cases and 400 deaths 
amongst men due to breast cancer in the year 2015[1]. 
The risk of breast cancer is associated with multiple important factors. Age is one the 
most crucial factor[2]. The chances of breast cancer increase significantly with old 
age. American Cancer Society states among the first time detection of invasive ductal 
carcinoma cases, 33% of the women are 55 or above[1]. Gender is also a crucial factor, 
with significant risk in case of female rather than male. The risk is also associated with 
genetic factors or in other words it can be hereditary in nature. Out of all cases limited 
number of cases, that is 5% have hereditary mutations in breast cancer associated 
genes BRCA1, BRCA2 and TP53[3]. There is an increased chance of breast cancer 
when a direct relative suffers from it. Apart from age, gender, hereditary mutations 
other factors like menarche, menopausal age, obesity and ethnicity are found to be 
associated with breast cancer. Lifestyle habits like diet, smoking, exposure to 
radiation seem to have associated with occurrences of breast cancer. 
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Figure 1 Breast cancer incidence and mortality 
 
Source: International Agency for Research on Cancer (IARC) and World Health 
Organization (WHO)[4] 
Breast cancer can be treated. The percentage of survival has increased in present 
times as compared to few decades ago. This success can be contributed to the growth 
of knowledge about breast cancer as well as to the recent developments in medical 
science. Breast cancer can be treated either by surgery, chemotherapy or radiation. 
Studies have shown that combinatorial approach is more beneficial[5]. Treatment via 
surgery is literally the removal of cancer tissue from breast and for this purpose 
entire breast can be salvaged or infected part is dissected. In case of chemotherapy, 
drugs are administered to stop the growth of affected cells by blocking important 
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pathways involved in cancer progression. In some cases hormone blocking drugs or 
even monoclonal antibodies are administered depending upon the subtype of breast 
cancer. Radiation therapy involves bombardment of affected parts of breast with 
small amount of radiation which destroys cancer cells. Most of these methods have 
serious side effects including severe damage of neighboring healthy cells.  
1.2 Breast Cancer Classification 
As mentioned earlier breast cancer is heterogeneous in nature. It is therefore 
necessary to classify breast cancer into different types in order to capture the 
characteristic essence of individual elements of this heterogeneous disease. Each 
subclass of cancer are driven by characteristic features which may vary across the 
subclasses making breast cancer treatment difficult. There is no single treatment for 
all the subclasses. In fact each of the subclasses may have different treatment regimen 
consisting of two or more therapies or even combination therapy[5]. There are 
numerous method for classifying breast cancer and each of them is based on different 
principles. Some of the classification methods are stage, grade, histopathology and 
receptor status. All most all of these tests require study of cancer tissues. Generally 
procedure such as biopsy is used to obtain a small portion of breast cancer tissue from 
the patient (i.e. surgically removed) and is used for classification as well as further 
genetic analysis  
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Stage 
This method of breast cancer classification is based on visual observation of cancer 
tissue obtained from patients. One of the most common method belonging to this 
category is TNM classification. This method was developed by Pierre Denoix and is 
maintained by Union of International Cancer Control[6]. This classification method is 
applicable to all forms of cancers and is not limited to breast cancer. 
T – Denotes size of the tumor 
N – Denotes the spread of the tumor to nearby lymph nodes 
M – Denotes that cancer has undergone metastasis i.e. it has spread and 
infected other part(s) of the body  
Further stages for breast cancer are denoted as follows 
 Stage 0 – Cancer is limited to tissue of origin 
 Stage 1, 2 & 3 – Cancer has grown in size and has affected lymph nodes 
 Stage 4 – Cancer has metastasized and spread to other part(s) of the body   
Grade 
 Grade is a classification method based on differentiation of cancerous cells. A normal 
cell of breast is well differentiated and is designated to carry out a specific function. 
Like ductal cells are responsible for the formation of ducts. In cases of cancer these 
specialized cells begin losing their specialization/differentiation. Typically a 
pathologist would look at the biopsy sample and compare it with normal tissue to 
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determine dissimilarity or determine the amount of differentiation cancerous cells 
have lost. This classification method is applicable to all forms of cancers. The most 
used scale for grading is called as Elston-Ellis grade[6]. 
Grade 1 or low-grade – Small difference between normal and cancerous cells 
Grade 2 or intermediate-grade – Cancerous cells are moderately differentiated 
Grade 3 or high-grade – Cancerous cells completely lose their differentiation 
compared to normal cells  
Histopathology 
It is the direct observation of cancerous tissue obtained from biopsy. This is very 
common and foremost method where tissue samples are studied by a pathologist to 
determine the characteristic features. This method determines whether tissue 
exhibits in-situ or invasive behavior and other histologic features like inflammation, 
tubular and differentiation. Basic and important information like location of the 
tumor is also recorded. This method is also used to study other types of cancers.  
Receptor Status 
This is an important method for classification of breast cancer into subtypes based on 
the receptor information. Receptors are responsible in cell signaling.  Hormones or 
other protein molecules bind receptors present on the surface of cell and bring about 
desired change in cell. Breast cancer cells may sometime show the presence of 
receptors, which in fact helps in deciding the course of treatment. Biopsy samples are 
always checked for presence of the receptors. 
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Currently there are three major receptors which are observed in breast cancer cells.  
Estrogen receptor (ER) 
Progesterone receptor (PR) 
HER2/neu (HER2) 
Estrogen binds to estrogen receptor (ER). Breast cancer cells which have estrogen 
receptor require estrogen for their growth and are denoted as ER+. Almost one third 
of invasive breast cancer cases are ER+[7]. Similarly progesterone binds to 
progesterone receptors present on breast cancer cells. This is denoted by PR+. In case 
of HER2+, cancer cells over express HER2/neu protein which plays an important role 
in growth of cancer cells. 
Although the receptors are involved in growth of cancer cells, but they are quite 
important in treatment of cancer. Blocking of key hormones or proteins can stop the 
growth of cancer. Drugs have been designed to block hormones like estrogen and 
progesterone and thus help in treating ER+ and PR+ breast cancer cases. In case of 
HER/neu monoclonal antibodies are designed to bind to the protein and make it 
unavailable for cancer cells[8]. Due to the importance of receptors in cancer 
treatment new/other receptors are now being studied in detail.  
For classification purpose breast cancer cells can have all three, few (one/two) or 
none of the receptors. And most commonly used classification method based on the 
receptor status makes use of all three receptors in classification.  
Based on the receptors breast cancer can be classified as  
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1. Luminal A 
2. Luminal B 
3. HER2 positive 
4. Basal or Triple negative 
Luminal A subtype of breast cancer is characterized by presence of two receptor 
types. Estrogen receptors and progesterone receptors. This subtype does not show 
the presence of over expressed HER2/neu protein. To summarize Luminal A is ER+, 
PR+ and HER2/neu -.  
Luminal B subtype of breast cancer is also characterized by presence of two receptors 
types. Estrogen receptors and progesterone receptors. However this subtype does 
show the presence of over expressed HER2/neu protein. To summarize Luminal B is 
ER+, PR+ and HER2/neu +.  
Basically the luminal subtype is characterized by the presence of estrogen receptors 
alone[7]. 
HER2/neu positive subtype of breast cancer is characterized by the absence of both 
estrogen receptors and progesterone receptors. But this subtype is characterized by 
over expression of HER2/neu protein. To summarize it is ER-, PR- and HER2/neu +.  
Basal subtype is a special case. This subtype lacks estrogen receptors as well as 
progesterone receptors. Also cells do not show overexpression of HER2/neu protein. 
In fact it is also known as triple negative and this breast cancer subtype is denoted as 
TNBC (Triple Negative Breast Cancer). Most of the times the term Basal and TNBC are 
interchangeably used. This subtype is very difficult to treat as it does not have 
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important receptors. This subtype has poor prognosis and survival rate[7]. As there 
are drugs to block estrogen and progesterone and monoclonal antibodies for 
HER2/neu protein, these subtypes Luminal A, Luminal B and HER2/neu have 
comparatively better prognosis and survival rate[7]. 
In this study we will be using 4 subtype based breast cancer classification. 
Figure 2 Breast cancer classification and its subtypes[7] 
 
Source:[7] 
1.3 Breast Cancer Cell lines 
Cell lines are cell cultures which are grown in vitro in laboratory. In another words 
they are colonies of cells which are grown artificially under controlled conditions[9]. 
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Cell lines have great pharmacological importance as they are used to study effects of 
various drugs. Almost all drugs are to be tested on cell lines in pre-clinical settings 
making cell lines inevitable part of drug development. Further cell line can be used to 
study cellular mechanisms and to determine new potential drug target sites[10].  
Usually cancer cells are obtained from patient’s tumor and cultivated into cell lines. 
Cell lines obtained specifically from breast cancer cells are known as breast cancer 
cell lines. These cell lines are very important aspect of breast cancer research. They 
provide continuous source of homogenous cancer cells[11]. BT-20 was the first 
breast cancer cell line to be established in 1958[12]. However development of cancer 
cell line is very tedious process with low success rate. This is because cells often get 
contaminated by the stromal cells. Even today the number of breast cancer cell lines 
available is below 100[11]. 
Following is a list of 59 breast cancer cell clines used in this thesis obtained from 
Cancer Cell Line encyclopedia[13](CCLE). 
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CHAPTER TWO 
BACKGROUND 
2.1 Research in Breast Cancer 
Cancers are very intricate diseases. They abruptly start growing in the body. Various 
reasons are being cited for development of cancer but none of them have helped in 
eradicating cancer. It is therefore necessary to genetically study cancers. Because 
cancer cells arise from normal cells. Only after studying the genetic mechanism one 
can answer questions like what part of the genome is altered in case of cancer, what 
are the genes activated or overexpressed, which genes are inactivated or mutated and 
what sections of chromosomes are lost or gained. 
A lot of new studies are now being published which make use of advance techniques 
like microarray, next generation sequencing and mass spectrometry etc. Breast 
cancer studies have revealed many insights. Scientific studies have published 
methods to classify breast cancer. Based on important genes various assays are now 
present to classify and predict breast cancer. Some of these assays are commercially 
available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, 
Genomic Grade Index®)[14].  These methods use gene signatures to correctly 
estimate prognosis and thereby help in designing or choosing better therapy. 
Most of the available gene signatures assume that breast cancer is not a single disease 
but a complex disease and try to classify it into different subtypes. This subtyping 
allows better treatment as these subtypes have different mechanism and thereby 
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different targets. Also these signature address the problem of prognosis and avoid 
overtreatment of patients by correctly identifying the type of breast cancer[14].  
A brief information of commercially available methods. 
PAM50 classifier 
PAM50 classifier uses 50 genes as a gene signature to classify the breast cancer[14]. 
The reported subtypes are Luminal A, Luminal B, HER2 and Basal. Actually it is a 
trained classifier which utilizes feature of 50 genes to classify breast cancer into one 
of the four types. This technique is based on Nanostring nCounter technology[15].  
The list of 50 genes[16]. 
Table 1 List of PAM50 genes[16]. 
ACTR3B ANLN BAG1 BCL2 BIRC5 BLVRA CCNB1 CCNE1 CDC20 CDC6 
CDH3 CENPF CEP55 CXXC5 EGFR ERBB2 ESR1 EXO1 FGFR4 FOXA1 
FOXC1 GPR160 GRB7 KIF2C KRT14 KRT17 KRT5 MAPT MDM2 MELK 
MIA MKI67 MLPH MMP11 MYBL2 MYC NAT1 NDC80 NUF2 ORC6L 
PGR PHGDH PTTG1 RRM2 SFRP1 SLC39A6 TMEM45B TYMS UBE2C UBE2T 
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MammaTyper 
MammaTyper is a kit which helps in classification of breast cancer into above 
mentioned four types on the basis of mRNA levels of four important genes. This 
technique quantitatively measures ER, PR, HER2 and Ki67 based on mRNA levels. The 
kit was developed by BioNTech AG[14]. It is also a classifier which uses information 
of the four genes generated from qRT-PCR to classify breast cancer. This method is 
good at distinction between Luminal A and Luminal B as it uses Ki67 level for 
identification of the subtype[14].  
Mammaprint 
This assay was developed by Agendia BV[14]. This method is based on gene signature 
of 70 identified genes. Mammaprint is predictive test which utilizes the information 
obtained from the 70 gene set to identify the risk of metastasis in breast cancer 
patient. Mammaprint is used to determine the chances of recurrence of breast cancer 
after 5 years and thus helps in determining the survival analysis. It classifies the 
patient into low risk and high risk of cancer reoccurrence[14]. 
Oncotype DX 
This assay was developed by Genomic Health Inc. It is most widely used gene 
expression assay. This method is based on set of 21 genes. Most of these genes are 
related to ER, HER2 and proliferation and are measure of their characteristics. 
Oncotype DX is very good prognostic as well as predictive test. The result of such test 
provides risk assessment in treated breast cancer patient for its reoccurrence. 
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Oncotype DX classifies patient into three risk zones based on the 21 gene classifier, 
as high risk or moderate risk or low risk[14]. 
Endopredict 
This test was developed by Sividon Diagnostics GmbH[14]. It is a prognostic test. The 
gene signature consist of 12 genes. However the prognosis is limited to ER + and 
HER2 – cases of breast cancer patients. Out of 12 genes, 4 genes are used as internal 
control while the 8 genes are used in assay to predict the risk of reoccurrence in case 
of treated breast cancer patients.  The scoring system ranges from 0 to 15 and 
classifies patients as low risk or high risk[14].  
Genomic Grade Index 
This index was developed by Ipsogen S.A., Marseille. It is based on gene set which 
contains 97 genes. Genomic grade index is a prognostic test. The test is good for ER + 
breast cancer patient and also helps in grading breast cancer tumors. The result from 
the index gives risk of reoccurrence of cancer in next 5 years in patients who are 
completely cured. Generally it classifies patient based on 97 gene sets as high risk or 
a low risk patient[14]. 
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Table 2 Table of gene signature based commercial assays[14]. 
Name of Assay Type of Test Technology 
Signature 
gene set 
Result 
(Subclass/ 
risk) 
PAM50 
Classifier, 
prognostic test 
Nanostring 
nCounter 
50 genes 
4 class 
subtyping 
MammaTyper Classifier qRT-PCR 4 genes 
4 class 
subtyping 
MammaPrint 
Prognostic & 
predictive test 
DNA 
microarrays 
70 genes 
low risk vs. 
high risk 
Oncotype DX 
Prognostic & 
predictive test 
qRT-PCR 16 genes 
high vs. 
moderate 
vs. low risk 
Endopredict Prognostic test qRT-PCR 8 genes 
low risk vs. 
high risk 
Genomic Grade 
Index 
Prognostic test 
DNA 
microarrays 
97 genes 
low risk vs. 
high risk 
 
Many breast cancer studies focus on one or two technologies. They themselves reveal 
lot of information by putting together the data and analyzing it. Studies have used 
mRNA expression profiling, DNA copy number analysis and also next generation 
sequencing techniques in combination [17-19].  
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The Cancer Genome Atlas is an organization with an aim to catalogue all the genetic 
mutations responsible for cancer[19]. TCGA has collected data about breast cancer 
using 6 different technologies. This has resulted in identification of many subtype 
specific mutations. Mutations accompanied with copy number alterations can reveal 
many drug targets. This breast cancer study cohort consisted of 825 patients[19]. 
Exome sequencing data is available for 510 tumors amongst 507 patients[19]. mRNA 
sequencing using Agilent platform was done for 547 samples , while copy number 
changes were detected using Affymetrix 6.0 single nucleotide polymorphism  array 
(SNP- array)[19]. 
 The study detected that certain mutations are associated with subclass of breast 
cancer. Nearly half of luminal A subtype were seen to have mutation in PIK3CA gene, 
luminal A was also dominated by MAP3K1 and MAP2K4 mutations[19]. The study 
reported that luminal A subtype was enriched in specific mutations in 3 genes 
(GATA3, PIK3CA, MAP3KI) while 29 % luminal B cases had TP53 and PIK3CA 
mutations. Samples of HER2 subtype of breast cancer show overexpression of HER2 
and also had the characteristics TP53 (72%) and PIK3CA (39%) mutations. Samples 
belonging to basal class had characteristics TP53 mutations mainly in the version of 
non-sense and frame-shift mutations[19]. The study also compared and stated that 
basal subtype had lot of similarities with high-grade serous ovarian tumors and 
suggested that they may share drug targets on basis of commonalities. 
TCGA also has a data portal where all the data is made available to researchers. Along 
with data from different technologies TCGA also have different types of data such raw 
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data to various forms of annotated data. Depending upon the annotation the data is 
assigned different levels. Level 3 is the highest annotated level and completely devoid 
of any patient information. Data which does not have any patient information is 
generally available for public to download freely. However access is controlled for 
different levels and access can be granted for research purposes after filing an 
application. Currently TCGA holds data for 34 types of cancer[19]. 
 Knowledge gained about cancer from systematic research is interpreted for 
development of tumor biology and therapeutic opportunities. The outcomes must be 
verified and confirmed with the help of model system [13]. Cell lines provide to be a 
great model system. They are like the photographs of cells and actually reflect the 
genomic diversity of the cancers. Plus they are continuous source of homogenous 
cells. The results obtained using such cells are reproducible due to their continuous 
and homogenous nature. Further cell lines are easily available as an effort of 
commercial cell line banks like American Type Cell line collection (ATCC). These cell 
line banks maintain, cultivate and distribute numerous cell lines. As a result of which 
outcome obtained using cell line as model in one laboratory can be replicated at other 
laboratories.  
Genomic profiles of cell lines must be studied. There are several cell line databases 
which have compiled together various omics aspect of cell lines. Cancer Cell Line 
Encyclopedia (CCLE) is one such database which has large collection of cell lines[13]. 
In fact it has 947 human cancer cell lines representing over 36 tumor types. CCLE 
holds gene expression, chromosomal copy number as well as massively parallel 
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sequencing data for the 947 cell lines of human origin. CCLE has also profiled 24 
anticancer drugs against approximately 500 of these cell lines. There are 59 breast 
cancer cell lines in CCLE. CCLE has significantly helped cancer studies by annotating 
pre-clinical human cancer models. CCLE is maintained by the Broad institute and 
Novartis[13]. 
Figure 3 Pie chart showing different cell lines at CCLE[13]. 
 
Source: CCLE[13] 
There are few other cell line databases. COSMIC (Catalogue of somatic mutations) is 
a database of somatic mutations. COSMIC cell line is part of the project. In cell line 
project all somatic mutations reported from literature survey are listed. 
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Simultaneously next generations sequencing methods are used to report somatic 
mutations. This database is developed by Wellcome Sanger Institute[20]. 
Another database called LINCS (Library of Integrated Network-based Cellular 
Signatures) exists with an aim to understand biological systems in healthy and 
diseased condition using networks. The outcome thereby can help in drug and 
biomarker development[21]. The ultimate goal is to completely understand cellular 
functions and their variance in normal and diseased conditions. A part of the data 
base called HMS LINCS deals with collection of information generated by the action 
of small experimental reagents on various model cell lines. As of March 2014 there 
were 1096 different cell lines. This database is maintained by Harvard[21]. 
Profiling Cancer Cell-line Sensitivities with Small Molecules (PCCSSM) is another 
database of cell lines developed by the Broad Institute[22]. PCCSSM maintains a 
record of information generated by the action small molecules like kinases and other 
small but potential drug compounds. The database has around 242 cell lines. PCCSSM 
does have DNA copy number data and mRNA gene expression data. PCCSSM is part of 
CTD2 (Cancer target Discovery and Development ) database at Broad[22]. 
GDSC (Genomics of Drug Sensitivity in Cancer) is database developed by Sanger 
Institute[23]. The aim of this study is to predict the response of anticancer drug on 
the basis of molecular features of cancer. GDSC has a total of 138 compounds which 
are sequentially tested on 714 cell lines by using different drug concentration and 
recording various parameters like AUC (Area under the Curve), drug dosage and 
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IC50[23]. GDSC also has gene expression values for cell lines determined using 
Affymetrix platform[23]. 
 
2.2 Thesis Statement 
Breast cancer is heterogeneous in nature. It is very important to determine the 
subtype of breast cancer.  As mentioned earlier that there are almost different course 
of treatment for luminal A, luminal B, HER2 and basal subtypes. The difference in 
treatment is due to the molecular features or genomic characteristics of each tumor 
subtype. A great deal of research is done on breast cancer and its subtype to identify 
changes in the molecular function and cause of these changes. The therapeutic targets 
revealed from these studies are being utilized for drug development.  
Drug development is a very difficult process. There are almost around thousands of 
potential starting molecules. However very few potential molecules can make into the 
market[24]. One of the important step in drug development through which every 
molecule has to pass is determining effects of it on various models. Cell line are very 
important models in case of breast cancer. 
It is very important to check the efficacy of potential molecule during drug 
development on the cell line in case of breast cancer. The molecule will perform better 
when the cell line shows presence of therapeutic target. Simultaneously the cell line 
should also have similar genomic characteristics as breast cancer subtype against 
which the molecule is designed. For this purpose it is necessary to compare the cell 
lines across tumor subtypes to determine the genetic similarity. 
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 It is evident from PubMed citations that very few of the breast cancers have been 
studied in details. The most commonly studied breast cancer include MCF-7, MDA-
MB-231, MDA-MB-468, SK-BR-3, T-47D and ZR-75-1 with each of them occurring in 
more than 500 PubMed citations. 
Figure 4 PubMed citations of breast cancer cell lines 
 
 
The goal of this thesis is to classify breast cancer cell line into tumor subtype based 
on the genomic profile comparison between tumor samples and breast cancer cell 
lines.  There are very few breast cancer studies which compare tumor samples and 
cell lines with respect to genetic profile [25, 26]. This thesis compares tumor and cell 
lines of breast cancers using DNA copy number data from Affymetrix platform. An 
attempt is made to compare gene expression data (Affymetrix platform) between 
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tumors and cell line samples. Apart from that comparison is made between sections 
of genome altered in breast cancer tumors and cell lines. Mutational frequencies of 
important genes involved in breast cancer, obtained from mutation annotation 
format a product of downstream processing of massively parallel sequencing data, 
were compared between tumors and cell lines. All this data put together gives a fair 
idea about various cell lines and their genomic features along with possible subtypes 
of breast cancer they might more strongly associate. 
This thesis has two fold objective. 
1. Detect subtype information of the cell line with no prior information. 
There are few cell lines which do not have any prior subtype information. 
Literature survey of these cell line did not yield any information of their 
subtype. 
2. Classify all cell lines into a subclass using genomic profile. 
Comparison of genomic features of tumor subtype with cell lines will help in 
classifying all cell lines into a particular tumor subtype. 
  
23 
 
CHAPTER THREE 
METHODOLOGY 
3.1 Data Acquisition 
All the data used in this thesis was downloaded from various data portals. These 
portals support unrestricted and free download of their data for research purposes. 
DNA copy number and mutation data for tumors was downloaded from TCGA data 
portal[19]. The total number of breast cancer samples present at TCGA was 1078 at 
the time of this thesis[19]. The DNA copy number data was available for 1049 
samples. Mutation data was available for 992 samples. Not all samples from TCGA 
could be used in mutation related analysis. All the data downloaded from TCGA was 
level three data which was devoid of any patient information. All samples used in the 
analysis were tumor matched. 
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Figure 5 TCGA data portal[19]. 
 
Source: TCGA website 
 (https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm?mode=ApplyFilter) 
CCLE has an impressive collection of 947 human cancer cell lines[13]. The total 
number of breast cancer cell lines is 59. DNA copy number data, mutation data and 
mRNA expression data for the breast cancer cell lines was downloaded from CCLE 
data portal. DNA copy number data and mRNA expression data was available for 59 
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cell lines. Mutation data was available for 51 cell lines. CCLE data portal requires 
signing in for free download of the data[13].  
The mRNA expression data for tumor samples could not be used from TCGA because 
of microarray platform used at TCGA was different than that present at CCLE. Because 
of this straightforward comparison of mRNA expression data from TCGA and CCLE 
was not possible. To compare the mRNA expression values of CCLE different datasets 
were downloaded from Gene Expression Omnibus (GEO) for tumor samples. GEO 
data set (GSE-41998) consisted of 279 tumor samples[27]. The data set also had the 
histopathology information which was used in classifying the tumor samples into 
subtypes. Both CCLE and GEO data sets use Affymetrix platform for mRNA expression. 
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Figure 6 CCLE data portal[13]. 
 
Source: CCLE website 
(http://www.broadinstitute.org/ccle/data/browseData?conversationPropagation=
begin) 
Mutation analysis required some other essential files. ‘WIG’ format file which has the 
number of reads for each region was downloaded from CCLE data portal. In case of 
TCGA, bed files derived from ‘WIG’ files were available at for few samples at Synapse, 
a research sharing platform (https://www.synapse.org/#!Synapse:syn1695394).   
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3.2 Technology Background 
DNA copy number 
It is the measure of variation between genomes. One such example is difference 
between cancer and normal genome. The cancer genome may have certain regions of 
DNA which have either more than one copy or the region might be missing. In short 
it is a measure of structural variants present in genomes to be compared. One of the 
method to determine copy number variation is array based comparative genomic 
hybridization. In this method DNA from normal and cancer sample is obtained and 
fragmented, further each of the sample is labelled with different fluorescent dye. Dye 
labeled samples are made to hybridize with probes on array and washed to remove 
unbound DNA. Array is designed in specific manner such that it has probes 
representing specific region of the DNA. In case if the cancer sample has duplication 
it has more copy of DNA representing that particular region. Hence more of the cancer 
sample will bind to the probes and that particular region on array will glow with 
fluorescence of cancer labeled dye. In case the cancer sample has deletion no binding 
will occur and array region will emit fluorescence of normal labelled dye. 
Affymetrix Genome –wide human SNP array 6.0 was used to detect the copy number 
variation in cancer samples at TCGA and CCLE. The result obtained from this array 
was processed and a downstream product called segmented file were used for further 
analysis.  
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Mutation 
Mutation in cancer samples was detected using massively parallel sequencing 
method. In this sample DNA is broken down into very small fragments of around 100 
bps. The fragments are further amplified. Then each of the fragment’s sequence can 
be identified using variety of proprietary mechanisms. The sequence obtained is then 
mapped against normal reference sequence. With help of variant calling tools variants 
or mutations in cancer genome if any are detected. The result is processed and one of 
the downstream product called mutation annotation format (.maf) file which records 
all mutations present in the sample was used for mutation analysis. 
mRNA expression data 
Expression of mRNA in a sample genome can be detected using array. mRNA’s are 
converted into complimentary DNA’s (cDNA). These cDNA’s are labeled with dye and 
are then hybridized with probes on array.  Array has a collection of multiple copy 
probes representing various genes.  The fluorescence form hybridized DNA and 
probes complex in measured optically and converted into numerical value depending 
upon the strength of fluorescence. These value in turn represent the quantity of 
mRNA in sample genome. Affymetrix platforms were used for mRNA expression at 
GEO and CCLE. GSE41998 used Affymetrix Human-Genome U133A 2.0 0 (GPL571) 
array with 22277 probes while CCLE used Affymetrix Human-Genome U133A Plus 
2.0 (GPL570) with 54675 probes. Affymetrix GPL570 platform has all 22277 probes 
present on GPL 571 platform.  
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3.3 Data Analysis 
3.3.1 Copy number data processing 
3.3.1.1 FGA (Fraction Genome Altered)[28] 
DNA copy number data was present in form of segmented file. Segmented files were 
available for TCGA tumor samples and CCLE cell line samples. Segmented files were 
used to calculate FGA. Fraction genome altered is a ratio. Here length of segments 
having value equal to or greater than a set threshold  are added and are divided by 
the sum of length of all segments. 
 
𝐹𝐺𝐴 = ( ∑ 𝐿(𝑖)/ ∑ 𝐿(𝑖) )
𝐶𝑁𝑖>𝑇
 (1)[28] 
 
The equation represents that sum lengths of all segments (L(i)) whose copy number 
(CN) is above the set threshold (T) and divide by sum of lengths of all segments 
(L(i))[28]. In case of threshold it was set to 0.2 for tumor samples and 0.3 for CCLE 
cell line samples. The threshold values were based on the paper from where this 
concept of FGA was loaned[28]. The reason for lower threshold in case of tumor 
sample was due to contamination of tumor samples by other normal cells or also due 
to tumor heterogeneity. The cell lines were considered free of such aberration. 
3.3.1.2 Correlation between TCGA and CCLE copy number data 
The segmented files were converted into gene files where segments were replaced by 
gene/genes lying in corresponding segment region for both TCGA data and CCLE data. 
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This segment to gene conversion was made possible with the help of Bioconductor 
package called ‘CNTools’ [29]. CNTools helps in mapping gene back to a segment to 
which the gene belongs. These files with gene and copy number value were used for 
correlation. Clinical information file containing histopathological data of tumor 
samples was also available[19]. This information was used to classify tumor samples 
into subclass luminal A, luminal B, HER2 and TNBC. Only 628 samples could be 
classified using the receptor information (luminal A= 59, luminal B=419, HER2=30, 
basal=120). Each of the subtyped tumor class was grouped together in a file and 
correlated with all cell line samples. The correlation was computed in R using the 
function called ‘cor’[30] . Thus all cell lines were correlated with four files generated 
from four tumor subtypes. Mean correlation was obtained for each cell line and tumor 
subtype and based on the highest correlation value cell line was classified into one of 
the four subtypes. 
3.3.2 Mutational frequencies 
Mutational frequencies were determined from data obtained from massively parallel 
sequencing technique. Mutational frequency can be described as a ratio of total 
number of mutations in the sample to total number of sample bases covered in 
sequencing. Actually it is the measure of total number of mutations detected out of 
total number bases sequenced. Mutations were limited to somatic mutations and 
functional mutations. Hence intronic, silent and other mutations were ignored and 
only exonic mutations were considered[28]. Mutations were reported as mutations 
per MB. 
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The number of mutations were obtained directly from .maf files for TCGA and CCLE. 
The number of bases for TCGA were detected from bed files. Bed file contains number 
of bases covered for each chromosome in form of start and end location. Subtracting 
end from start gives number of bases covered by the reads. All bases obtained for 
each sample were summed together to give us the number of bases covered for that 
sample. In case of CCLE, wig formats provides number of reads covering each base. 
So summing up all bases where there is read count will give the total number of bases. 
3.3.3 Correlation between GEO and CCLE mRNA expression data 
Raw files of microarray mRNA expression in form of ‘CEL’ files were downloaded 
from GEO and CCLE data portal. All the raw data was generated using Affymetrix 
platforms. Data to be compared between experiments had to be made comparable 
using methods such as back ground adjustments and nonspecific binding correction 
for which normalization algorithms were available. Affymetrix MAS5.0 normalization 
algorithm was used to normalize raw data. Clinical data was also available for GEO 
samples and based on receptor information GEO samples were divided into four 
subtypes luminal A, luminal B, HER2 and basal.  There were 77 samples in luminal A 
group, 7 in luminal B, 16 in HER2 and 140 samples in basal group. All cell line samples 
were correlated with each of the four groups and correlation values were calculated 
in R[30]. Mean correlation value was calculated for each cell line and a group. Cell line 
was classified to a group with which it had highest correlation value.  
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3.3.4 Classifier 
A classifier was developed to classify samples into luminal or basal based on the 
proportion of significantly mutated genes. The .maf files reported all mutated genes 
along with the types of mutation. For classifier TCGA samples were bifurcated into 
two classes. One class consisted of all luminal A and luminal B samples while the other 
class consisted only basal samples. The proportion of mutated genes for all samples 
were calculated for each class separately. The genes were sorted in decreasing order 
based on the difference in proportion. The genes with highest difference in 
proportion were deemed significant. These significant genes were further used to 
develop and train the classifier. Classifier was based on generalized linear model 
(GLM) under the assumption that there exist a linear relationship between the 
mutated genes. As the response variable was binary (luminal=1 and basal=0) logistic 
regression was used to detect the predictor variables (slope and intercept) from 
regression. These predicted variables were used to calculate the outcome of testing 
samples (In sample) as well as cell line samples (Out of sample). Majority of samples 
(70%) from TCGA were used to train the classifier and remaining (30%) served as 
testing samples. The classifier was optimized for number of variables starting from 
fifty variables. The optimized classifier was then used to classify the CCLE samples 
into luminal or basal. 
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3.3.5 PubMed citation analysis 
The use of breast cancer cell lines in research can be best studied using PubMed 
citations. The number of citations can not only provide an estimate about cell lines 
being used in research but also suggests which cell line is most widely used.  
PubMed search builder (http://www.pubmed.org) was used on January 21st 2015 to 
determine the number of citations for all breast cancer cell lines at CCLE. Various 
punctuation alternatives were used for each cell line. The number of citations cannot 
be considered final as there might be few false negative in the search. 
Perl and Python were major scripting languages used in the analysis of data. R was 
used to perform statistical analysis and plotting graphs. Integrative genomic viewer 
(version 2.3) was used to create copy number profile plots[31]. 
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CHAPTER FOUR 
RESULTS 
TCGA paper found that luminal A, luminal B and HER2 samples show mutation in 
PIK3CA gene[19]. Luminal A was dominated with large number of samples with 
PIK3CA mutation along with mutation in other genes[19]. Luminal B had 
characteristic PIK3CA and TP53 mutation[19]. HER2 samples had characteristic 
PIK3CA and TP53 mutation along with HER2 gene amplification[19]. While TP53 
mutation was present in Basal samples[19] 
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4.1 FGA 
Figure 7 Fraction Genome Altered 
 
 
It is evident from figure 7 that copy number alteration are significantly common in 
TCGA as well as CCLE. The median fraction of genome altered in TCGA is around 17% 
and 45% for CCLE. This indicates that cell line samples are subject to more copy 
number alterations. Nevertheless both datasets show wider distribution, this can be 
attributed to different subtypes present in TCGA as well as CCLE, as each of the 
subtype have different characteristic mutations and copy number profiles[28].  
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4.2 Mutation Frequencies 
Figure 8 Mutation frequencies 
 
 
The above figure 8 illustrates the number of mutation per million bases for TCGA 
samples and CCLE samples. The median mutational frequency for TCGA is around 1 
while for CCLE it is around 5. In case of CCLE the mutational frequency were available 
for only 1651 genes which the study considers important in cancer development, 
whereas TCGA captured all somatic mutations present in the genome. The reason for 
cell lines having more mutational frequencies is well defined in another study related 
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to ovarian cancer[28].  One of the reason cited is that cell lines being more pure 
capture more mutations than tumor samples which many times get contaminated 
with stromal cells. Another reason is cell lines may transform due to numerous 
passages over the period of time. Alternatively CCLE has reported all mutations 
including germline mutations which are excluded from TCGA tumor samples[28].  
 
4.3 Hypermutation 
Figure 9 Comparison between Fraction Genome Altered and Mutational frequencies 
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From the figure 9 it can be seen that CCLE cell lines have a higher number of mutation 
compared to TCGA tumor samples. But both the data sets have similar number of copy 
number alterations. However one of the CCLE cell line (HCC1569) is reported with a 
very high mutational frequency, above 15 mutation per million bases.  This clearly 
indicates that the cell line shows hypermutation. 
 
 
 
 
39 
 
4.4 Copy Number Profiles 
Figure 10 Copy number profiles for TCGA tumor samples 
 
This figure provides copy number profiles for all tumor samples in TCGA (1049 
samples).The copy numbers are shown for each chromosome. The red color indicates 
higher copy number value while the blue color indicates lower copy number value. 
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IGV helps to visualize all samples in a single frame and also supports zooming in to a 
particular chromosome or even a gene or a certain region of the chromosome[31]. 
Figure 11 Copy number profiles for CCLE cell line samples 
 
This figure provides copy number profiles for all cell line samples in CCLE (59 
samples).The copy numbers are shown for each chromosome.  The red color indicates 
higher copy number value while the blue color indicates lower copy number value. 
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IGV helps to visualize all samples in a single frame and also supports zooming in to a 
particular chromosome or even a gene or a certain region of the chromosome[31]. 
4.5 Correlation Score 
4.5.1 Correlation score for copy number profiles 
Based on correlation scores obtained using Pearson correlation with TCGA tumor 
subtypes, each of the CCLE cell line was classified into a particular subtype. Out of 59 
CCLE samples based on the correlation score 23 samples were classified as Luminal 
A, 9 as Luminal B, 7 as HER2 and 20 samples were classified as basal. 
Figure 12 Copy number based correlation 
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Above figures have 59 bar plots representing each of the 59 CCLE cell lines. For each 
subtype plot, few cell lines have been called out which have been classified into that 
particular subtype and have the highest correlation score. 
4.5.2 Correlation score for gene expression profiles 
Correlation score was calculated for each CCLE cell line and TCGA tumor subtype 
based on Pearson correlation. Out of 59 CCLE samples based on gene expression 
correlation score 2 samples were classified as Luminal A, 11 as Luminal B, 21 as HER2 
and 25 samples were classified as basal. 
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Figures below have 59 bar plots representing each of the 59 CCLE cell lines. For each 
subtype plot, few cell lines have been called out which have been classified into that 
particular subtype and have the highest correlation score. 
Figure 13 Gene expression based correlation 
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4.6 Classifier 
The GLM (logistic regression) based classifier was trained and tested on TCGA (in 
sample) data. It was found that the classifier had better accuracy when it used 50 
variables as genes (significant genes based on proportion). These 50 variables were 
feed to step function, which uses stepwise AIC algorithm to generate a model. 
Sensitivity, specificity and AUC was determined for both training and test datasets. 
The classifier’s training efficiency for predicting luminal samples based on 5 random 
trials (selection of samples) yielded sensitivity ranging from 81% to 86%, while 
specificity ranged from 79% to 90% and AUC ranged from 91% to 93%. In case of 5 
testing trials sensitivity ranged from 78% to 89% while specificity ranged from 60% 
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to 90% and AUC ranged from 80% to 85%. The number of genes used as variables 
varied from 16 to 23.  
However CCLE has mutation data for 1651 genes. And only 11 significant genes 
overlapped between TCGA and CCLE datasets. The model based on 11 genes as 
variables yielded following results. The classifier’s training efficiency for predicting 
luminal samples yielded sensitivity of 82%, while specificity of 74%. And AUC 
obtained was 85%. In case of testing the sensitivity was 79% while specificity was 
81% and AUC obtained was 87%.  
4.7 Cell line Classification 
Table 3 Classification of CCLE cell lines into four tumor subtypes 
Cell line 
name 
PubMed 
Citations 
Gene 
Expression 
based 
Classificati
on 
Copy 
number 
based 
Classificati
on 
Classifier 
based 
Classificati
on 
Classificati
on from lit. 
survey 
      
AU565 41 HER2 HER2 Basal 
HER2amp 
[32] 
BT20 430 Basal Basal Luminal Basal [32] 
BT474 428 HER2 Luminal A Luminal 
HER2amp 
[32] 
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BT483 12 Luminal B Luminal B Luminal Luminal 
BT549 148 Basal Basal Luminal Basal[32] 
CAL120 181 Basal Luminal A Basal 
Luminal 
B[33] 
CAL148 57 HER2 Luminal B Luminal 
Luminal 
A[33] 
CAL51 9 Basal Basal Luminal  
CAL851 183 Basal Basal Luminal Basal[33] 
CAMA1 41 HER2 Luminal A Luminal Luminal A 
DU4475 28 Basal Luminal B Luminal Basal 
EFM19 18 HER2 Luminal A Luminal Luminal[34] 
EFM192A 1 HER2 Luminal A Luminal 
Luminal 
B[34] 
EVSAT 48 HER2 Basal Luminal  
HCC1143 12 Basal Luminal A Basal 
Basal[25, 
35] 
HCC1187 5 Basal Basal Luminal Basal[32] 
HCC1395 6 Basal Basal Luminal Basal[32] 
HCC1419 1 HER2 Luminal A Luminal 
HER2amp[3
2] 
HCC1428 4 HER2 Luminal A Luminal Luminal[32] 
HCC1500 13 Luminal A Luminal A Luminal Luminal[32] 
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HCC1569 6 Basal Basal Luminal 
HER2amp[3
2] 
HCC1599 2 Basal Basal Luminal Basal[32] 
HCC1806 29 Basal Basal Luminal Basal[32] 
HCC1937 121 Basal Basal Basal Basal[32] 
HCC1954 40 HER2 HER2 NA 
HER2amp[3
2] 
HCC202 0 HER2 Luminal A Luminal 
HER2amp[3
2] 
HCC2157 0 Basal Basal Luminal Basal[32] 
HCC2218 3 HER2 Luminal B Luminal 
HER2amp[3
2] 
HCC38 23 Basal Luminal A Luminal Basal[32] 
HCC70 18 Basal Basal Luminal Basal[32] 
HDQP1 2 Basal Basal NA  
HMC18 4 Basal Luminal A Luminal  
HMEL 22 Basal Luminal B NA  
HS274T 0 Luminal B Basal NA  
HS281T 0 HER2 Luminal A Luminal  
HS343T 0 HER2 HER2 Luminal Basal[32] 
HS578T 379 Basal Basal Luminal 
Basal[25, 
35] 
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HS606T 0 Luminal B Basal NA  
HS739T 0 Luminal B Luminal B Basal  
HS742T 1 Luminal B Luminal A Luminal  
JIMT1 62 Basal HER2 Luminal 
HER2amp[3
6] 
KPL1 26 HER2 Luminal A Luminal Luminal[34] 
MCF7 23201 HER2 Luminal A Luminal Luminal[32] 
MDAMB134V
I 
5 Luminal A Luminal B Luminal Luminal[32] 
MDAMB157 50 Basal Basal NA Basal[32] 
MDAMB175V
II 
5 Luminal B Luminal A NA Luminal[32] 
MDAMB231 7507 Basal Luminal A Basal Basal[32] 
MDAMB361 155 HER2 Luminal A Luminal 
HER2amp[3
2] 
MDAMB415 13 Luminal B Luminal A Luminal Luminal[32] 
MDAMB436 131 Basal Basal Luminal Basal[32] 
MDAMB453 350 HER2 HER2 Luminal Basal[32] 
MDAMB468 956 Basal Basal Luminal Basal[32] 
SKBR3 760 HER2 HER2 Basal 
HER2amp[3
2] 
T47D 795 Luminal B Luminal A Luminal Luminal[32] 
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UACC812 15 Luminal B Luminal A Luminal 
HER2amp[3
2] 
UACC893 9 HER2 HER2 Luminal 
HER2amp[3
2] 
YMB1 8 HER2 Luminal B NA  
ZR751 720 Luminal B Luminal B Luminal Luminal[32] 
ZR7530 59 Luminal B Luminal A Luminal 
HER2amp[3
2] 
 
FGA and mutational frequencies reveal information about TCGA and CCLE samples, 
but they alone are insufficient for classification of CCLE samples. The cell lines can be 
classified with more information obtained from correlation between copy number 
and gene expression datasets. These dataset comparisons in case of copy number 
account for amplification and deletion consistencies while gene expression account 
for characteristic expressions.  
Based on correlation information cell lines are classified into one of the four breast 
cancer subtypes. The Classifier trained on proportion of mutation in significant genes 
further aids to confirm CCLE cell line classification.  
The above table has classification for 59 CCLE cell lines based on correlation values 
obtained from copy number and gene expression datasets and this classification 
might be correctly identified and confirmed by classifier’s outcome.  
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Cell line BT 483 is classified as luminal based on literature survey is confirmed as 
luminal B subtype by the correlation analysis. The classifier also identifies it to be 
luminal cell line.  HCC1937 which is classified as basal cell line in literature is 
confirmed as basal by both the correlation results as well as by classifier’s outcome. 
Most of the times correlation analysis correctly classifies cell lines into subtype found 
in literature. However the classifier’s result are not always correct. This can be 
attributed to an error in classifier and therefore has a scope for improvement.  
There are few cell lines where there is none or very less information available in 
literature. Further their subtypes are unknown and also histopathological 
information is unavailable. Few such cell lines were classified using correlation 
analysis. One such example is HDQP1 which was classified as Basal from correlation 
analysis. HS739T and HS742T were classified as luminal by correlation analysis. 
Enlightening facts about cell lines with no prior information was one of the important 
objective of this thesis. And on the basis of correlation few of them have been 
classified into a subtype. Thus unclassified cell lines were successfully classified in 
this study. 
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CHAPTER FIVE   
DISCUSSION AND LIMTATIONS 
5.1 Discussion  
The goal of this thesis was to classify CCLE cell lines into one of the four breast cancer 
subtypes (luminal A, luminal B, HER2 and basal). This study has revealed valuable 
classification information about some cell lines which lacked earlier in depth studies. 
A careful study of tumor samples genomic parameters like copy number, gene 
expression and gene mutation data and comparison of it with cell line datasets has 
made possible cell lines classification based on a statistical measure known as 
correlation.  
There has always been an ambiguity about subtype classification of breast cancer cell 
lines even if the number of cell lines available for breast cancer cell line is low. It is 
below 100. Further based on the literature survey very few of these cell lines are 
widely used. This gives rise the need of classifying cell lines which will help in 
providing new cell line models for various tumor subtype researches. This study tries 
to address these needs by classifying the cell lines. 
Any cell line’s use as model depends upon the question being asked. For example does 
cell line possess same gene alterations as the tumor or does cell line share 
same/similar type of mutations in gene/genes?  Another question would be whether 
they share same genomic segment variation as in amplification or deletion? Also are 
gene expression pattern similar? These questions are very important during drug 
development as most studies target specific molecular mechanisms which should be 
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certainly present in model cell lines so as to confirm the pharmaceutical action of 
drugs. This study address similar problems by developing classification technique 
which uses all available genomic profiles to classify cell lines. Classification is done 
for each profile independently (copy number, gene expression and mutation). This 
ultimately provides measures of similarity of each cell line.  
Cell line once subtyped and annotated to particular class will greatly help in 
development of personalized medicine. Annotated cell line matched to an individual 
patients will definitely help in selecting an established treatment regime. As there are 
various databases including CCLE which test various anticancer drugs on all available 
cell lines and record the activity. These studies are not limited to anticancer drugs. In 
fact all possible agents right from small molecules inhibitors, kinases to custom 
compounds are being tested as potential drugs. 
5.2 Limitations 
This thesis represents an effort for classification of cell lines. Concepts used in this 
thesis for classification are distinctive but they are not all inclusive. One of the main 
limitation is classifier, it is not completely accurate and is innate as it produces lot of 
incorrect results. One reason can be inadequate number of variables used in its 
creation. The error can also be attributed to CCLE data as only 1651 genes are 
available whereas more than 15000 genes are available at TCGA. 
All the copy number analysis make use of segmented data. This segmented data is 
obtained from Affymertix SNP 6.0 platform. Even though the platform used at both 
the sources (TCGA and CCLE) are same there exist some artifacts in the data. Firstly 
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there exists some mechanical error occurred while conducting the experiments, 
many studies have also shown that even environmental conditions greatly affect the 
experiment outcome. However raw data obtained follow the same preprocessing and 
downstream processing at both sources which heavily normalize data to make it 
comparable across various other studies. Nevertheless these data normalization 
effort may not be sufficient enough to adjust for all errors and variations either 
internal or due to external factors. There should be additional steps involved where 
data for comparison is actually integrated and normalized together by using 
techniques like quantile normalization which can actually adjust for most of the 
variations and make the data more uniform. 
Mutational data consist of all mutations present in all genes of an individual. This data 
is obtained using next generation sequencing technology. TCGA has both matched 
tumor data and normal data which results in identification of both somatic and 
germline mutations by comparing tumor and normal data. However segregation of 
observed mutations in to somatic and germline mutations is not possible for cell lines.   
As cell lines are often generated from tumor samples besides many of these were 
established decades ago at a time where normal tissue was not recorded along with 
the tumor tissue. Therefore it not possible to match tumor cell line with its normal 
tissue. Hence tumor mutation data consist of both germline as well as somatic 
mutation. Often this mutational data discrepancy yields inconclusive results between 
TCGA and CCLE samples. 
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However there are databases like 1000 genomes and HapMap which have catalogued 
generally occurring variants in various human races. These variants can be used as 
baseline against both the tumor and cell line data which ultimately take care of 
commonly occurring and germline mutations. This is based on the premise that if we 
are aware of the race of an individual from whom the cell line was obtained then 
common variants in that particular race might cover most of the germline mutations. 
Nonetheless this premise needs to be tried, tested and further verified. 
Gene expression comparison between samples from different platform is not 
advisable. TCGA used Illumina platform for gene expression studies while CCLE used 
Affymetrix platform. In order to counter this problem a GSE study of breast cancer 
tumors was selected which was done on Affymetrix platform. Raw data was obtained 
from both sources. They were subjected to same pipeline and normalization 
techniques to make data comparable. However even for the same platform there are 
some chip artifacts which may affect the results. Also, as mentioned above human and 
environmental factors also affect the results to an extent. Method such as quantile 
normalization can adjust such artifacts by transforming original values to rank based 
values and thereby making them statistically comparable.  
Correlation is measure of relationship between two variables. Correlation is a good 
method for determining similarity between cell lines and tumor subtypes. When gene 
expressions were used as variables correlation method worked fine. But in case of 
copy number data correlation observed was very low. A better method such as 
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regression may be used to correctly identify the relationship which may result in 
better classification. 
The classification obtained using gene expression and copy number data was in 
agreement for most of the cell lines with their literature classifications. However in 
order to make an accurate classification a more advanced model system can be 
developed which can take in all the variables resulting in more congruent and better 
classification. This model can integrate gene expression values, copy number values, 
FGA and mutation data and assign a weight to each variable according to its 
significance which will lead into better prognosis.   
The result obtained from correlation analysis might not be accurate as small number 
of cell lines were available. In order to improve the result it is necessary to have large 
number of cell lines along with multiple replicates. 
Lot of issues exist with available data for tumors and cell lines. Mutational data is 
unavailable for all samples as some bed files of TCGA samples are missing. Also all 
samples at TCGA do not have genetic information for both genomic profiles of DNA 
copy number and mutation. Further platform used for gene expression at TCGA is 
different than CCLE which makes gene expression comparison difficult.   
This study is limited to cell lines available at CCLE however there are other databases 
which have additional breast cancer cell lines. It can also be stated that this study is 
limited to only one type of cancer (breast cancer). However similar concepts can be 
applied to other form of cancers. 
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Some of the limitations can be addressed with additional data. Nevertheless this study 
can definitely be a base for future work. 
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CHAPTER SEVEN 
APPENDIX 
 
Table 4 List of breast cancer cell lines from Cancer Cell Line encyclopedia[13]. 
Serial No. Name of cell line 
1 AU565 
2 BT20 
3 BT474 
4 BT483 
5 BT549 
6 CAL120 
7 CAL148 
8 CAL51 
9 CAL851 
10 CAMA1 
11 DU4475 
12 EFM192A 
13 EFM19 
14 EVSAT 
15 HCC1143 
16 HCC1187 
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17 HCC1395 
18 HCC1419 
19 HCC1428 
20 HCC1500 
21 HCC1569 
22 HCC1599 
23 HCC1806 
24 HCC1937 
25 HCC1954 
26 HCC202 
27 HCC2157 
28 HCC2218 
29 HCC38 
30 HCC70 
31 HDQP1 
32 HMC18 
33 HMEL 
34 HS274T 
35 HS281T 
36 HS343T 
37 HS578T 
38 HS606T 
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39 HS739T 
40 HS742T 
41 JIMT1 
42 KPL1 
43 MCF7 
44 MDAMB134VI 
45 MDAMB157 
46 MDAMB175VII 
47 MDAMB231 
48 MDAMB361 
49 MDAMB415 
50 MDAMB436 
51 MDAMB453 
52 MDAMB468 
53 SKBR3 
54 T47D 
55 UACC812 
56 UACC893 
57 YMB1 
58 ZR751 
59 ZR7530 
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Table 5 Copy number based correlation score and classification 
Cell lines 
Names 
Luminal 
A 
Luminal 
B 
HER2 Basal Classification 
Max. 
Score 
AU565 0.166586 0.154257 0.184331 0.122502 HER2 0.184331 
BT20 0.046715 0.031671 0.086495 0.110932 Basal 0.110932 
BT474 0.188798 0.109514 0.162058 0.086534 Luminal A 0.188798 
BT483 0.253735 0.253975 0.189633 0.174008 Luminal B 0.253975 
BT549 0.022708 0.051819 0.031989 0.067934 Basal 0.067934 
CAL120 0.072618 0.066888 0.046678 0.071756 Luminal A 0.072618 
CAL148 0.189672 0.270839 0.135863 0.1557 Luminal B 0.270839 
CAL51 -0.00547 -0.00421 -0.00496 -0.00409 Basal -0.00409 
CAL851 0.070278 0.047388 0.092087 0.148079 Basal 0.148079 
CAMA1 0.170342 0.170115 0.126597 0.100618 Luminal A 0.170342 
DU4475 0.140713 0.191345 0.11956 0.158038 Luminal B 0.191345 
EFM19 0.187921 0.138244 0.158837 0.127828 Luminal A 0.187921 
EFM192A 0.151507 0.110575 0.128764 0.058168 Luminal A 0.151507 
EVSAT 0.110345 0.087168 0.138484 0.138799 Basal 0.138799 
HCC1143 0.136037 0.109538 0.106757 0.097419 Luminal A 0.136037 
HCC1187 0.065842 0.116121 0.100467 0.180329 Basal 0.180329 
HCC1395 0.046239 0.051194 0.072145 0.101262 Basal 0.101262 
HCC1419 0.147093 0.131807 0.135331 0.125562 Luminal A 0.147093 
HCC1428 0.186741 0.183406 0.17101 0.183609 Luminal A 0.186741 
HCC1500 0.167727 0.159965 0.121797 0.134641 Luminal A 0.167727 
HCC1569 0.20042 0.183807 0.211373 0.222102 Basal 0.222102 
HCC1599 0.161995 0.133576 0.144028 0.165898 Basal 0.165898 
HCC1806 0.098709 0.071424 0.096514 0.104047 Basal 0.104047 
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HCC1937 0.103335 0.066144 0.103311 0.113123 Basal 0.113123 
HCC1954 0.1567 0.103305 0.181383 0.142198 HER2 0.181383 
HCC202 0.209316 0.190248 0.206212 0.18304 Luminal A 0.209316 
HCC2157 0.161396 0.157346 0.176477 0.199652 Basal 0.199652 
HCC2218 0.236173 0.237535 0.192882 0.156001 Luminal B 0.237535 
HCC38 0.129315 0.08599 0.108364 0.097608 Luminal A 0.129315 
HCC70 0.114064 0.114522 0.181384 0.216158 Basal 0.216158 
HDQP1 0.081337 0.044456 0.088894 0.131949 Basal 0.131949 
HMC18 0.098861 0.065408 0.069957 0.069847 Luminal A 0.098861 
HMEL 0.028209 0.032638 0.01176 -0.00318 Luminal B 0.032638 
HS274T -0.00293 -0.00184 -0.00044 0.001242 Basal 0.001242 
HS281T 0.000212 -0.00111 -5.3E-05 -0.00136 Luminal A 0.000212 
HS343T -0.00117 -0.00171 0.000114 -0.00243 HER2 0.000114 
HS578T 0.007327 -0.00725 0.043033 0.095946 Basal 0.095946 
HS606T -0.00253 -0.00116 -0.00138 -0.00058 Basal -0.00058 
HS739T -0.0026 -0.0002 -0.00242 -0.00074 Luminal B -0.0002 
HS742T -0.00213 -0.00226 -0.00384 -0.00331 Luminal A -0.00213 
JIMT1 0.131891 0.083575 0.139405 0.132754 HER2 0.139405 
KPL1 0.145989 0.139242 0.111829 0.092862 Luminal A 0.145989 
MCF7 0.177755 0.155327 0.131767 0.107978 Luminal A 0.177755 
MDAMB134VI 0.16867 0.177989 0.106024 0.068999 Luminal B 0.177989 
MDAMB157 0.136728 0.132104 0.135413 0.143768 Basal 0.143768 
MDAMB175VII 0.224016 0.21786 0.173201 0.117779 Luminal A 0.224016 
MDAMB231 0.070701 0.060817 0.048531 0.051681 Luminal A 0.070701 
MDAMB361 0.150759 0.087107 0.135484 0.087908 Luminal A 0.150759 
MDAMB415 0.106 0.083785 0.070655 0.045863 Luminal A 0.106 
MDAMB436 0.051987 0.099007 0.065526 0.10453 Basal 0.10453 
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MDAMB453 0.169822 0.14676 0.173551 0.113635 HER2 0.173551 
MDAMB468 0.034743 0.034994 0.095231 0.162813 Basal 0.162813 
SKBR3 0.161321 0.151328 0.176783 0.134858 HER2 0.176783 
T47D 0.197928 0.160988 0.132668 0.062742 Luminal A 0.197928 
UACC812 0.205642 0.145025 0.169032 0.095471 Luminal A 0.205642 
UACC893 0.205827 0.129598 0.242297 0.179517 HER2 0.242297 
YMB1 0.180665 0.201045 0.126246 0.120499 Luminal B 0.201045 
ZR751 0.188406 0.209278 0.128404 0.116821 Luminal B 0.209278 
ZR7530 0.253548 0.222583 0.207872 0.134416 Luminal A 0.253548 
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Table 6 Gene expression based correlation score and classification 
Cell lines 
Names 
Luminal 
A 
Luminal 
B 
HER2 Basal Classification 
Max. 
Score 
AU565 0.570026 0.57432 0.579763 0.576286 HER2 0.579763 
BT20 0.564632 0.567867 0.575154 0.575742 Basal 0.575742 
BT474 0.599571 0.602351 0.606111 0.599208 HER2 0.606111 
BT483 0.589095 0.589134 0.587257 0.579759 Luminal B 0.589134 
BT549 0.559006 0.562753 0.566721 0.570646 Basal 0.570646 
CAL120 0.590019 0.592141 0.594513 0.598636 Basal 0.598636 
CAL148 0.602213 0.60476 0.609575 0.604806 HER2 0.609575 
CAL51 0.580683 0.582498 0.587331 0.588143 Basal 0.588143 
CAL851 0.557406 0.560935 0.567473 0.571492 Basal 0.571492 
CAMA1 0.55942 0.560788 0.561223 0.558354 HER2 0.561223 
DU4475 0.517213 0.518507 0.522048 0.523279 Basal 0.523279 
EFM19 0.546366 0.548151 0.54819 0.545028 HER2 0.54819 
EFM192A 0.580619 0.583738 0.587441 0.581366 HER2 0.587441 
EVSAT 0.553026 0.555579 0.561578 0.559659 HER2 0.561578 
HCC1143 0.581157 0.58385 0.58917 0.59486 Basal 0.59486 
HCC1187 0.559603 0.561519 0.568442 0.572434 Basal 0.572434 
HCC1395 0.57537 0.578106 0.582776 0.587424 Basal 0.587424 
HCC1419 0.586698 0.589336 0.590237 0.58094 HER2 0.590237 
HCC1428 0.599791 0.602025 0.602648 0.600679 HER2 0.602648 
HCC1500 0.580554 0.58022 0.577432 0.573 Luminal A 0.580554 
HCC1569 0.511839 0.513867 0.518865 0.524124 Basal 0.524124 
HCC1599 0.53831 0.540238 0.54575 0.550942 Basal 0.550942 
HCC1806 0.52837 0.530124 0.530812 0.535139 Basal 0.535139 
66 
 
HCC1937 0.582408 0.585304 0.591811 0.597292 Basal 0.597292 
HCC1954 0.576913 0.580767 0.589402 0.589169 HER2 0.589402 
HCC202 0.565565 0.569084 0.573789 0.566555 HER2 0.573789 
HCC2157 0.521166 0.522985 0.528185 0.53164 Basal 0.53164 
HCC2218 0.538542 0.540795 0.542325 0.53553 HER2 0.542325 
HCC38 0.574749 0.576395 0.582056 0.585008 Basal 0.585008 
HCC70 0.570171 0.573132 0.57965 0.584247 Basal 0.584247 
HDQP1 0.56835 0.570672 0.573425 0.577578 Basal 0.577578 
HMC18 0.530087 0.532197 0.534592 0.539375 Basal 0.539375 
HMEL 0.473079 0.47269 0.474992 0.480046 Basal 0.480046 
HS274T 0.601471 0.607289 0.604908 0.605178 Luminal B 0.607289 
HS281T 0.592256 0.598214 0.598233 0.597762 HER2 0.598233 
HS343T 0.566836 0.572646 0.573177 0.573118 HER2 0.573177 
HS578T 0.577653 0.583453 0.584346 0.586865 Basal 0.586865 
HS606T 0.599365 0.604928 0.604132 0.60359 Luminal B 0.604928 
HS739T 0.534029 0.538806 0.537864 0.535947 Luminal B 0.538806 
HS742T 0.550857 0.555965 0.554277 0.55295 Luminal B 0.555965 
JIMT1 0.575458 0.578295 0.583062 0.586071 Basal 0.586071 
KPL1 0.602228 0.603976 0.606325 0.602303 HER2 0.606325 
MCF7 0.54375 0.544845 0.544922 0.542028 HER2 0.544922 
MDAMB134VI 0.518042 0.51605 0.514159 0.510426 Luminal A 0.518042 
MDAMB157 0.557329 0.56068 0.563801 0.566379 Basal 0.566379 
MDAMB175VII 0.55053 0.552245 0.550921 0.542686 Luminal B 0.552245 
MDAMB231 0.539184 0.54147 0.544249 0.547399 Basal 0.547399 
MDAMB361 0.580423 0.582531 0.586684 0.58096 HER2 0.586684 
MDAMB415 0.6126 0.615648 0.613167 0.605896 Luminal B 0.615648 
MDAMB436 0.568883 0.572186 0.577076 0.581384 Basal 0.581384 
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MDAMB453 0.598087 0.600993 0.606492 0.59937 HER2 0.606492 
MDAMB468 0.563058 0.565885 0.574286 0.578314 Basal 0.578314 
SKBR3 0.567165 0.570952 0.574411 0.570755 HER2 0.574411 
T47D 0.576485 0.577867 0.576657 0.572871 Luminal B 0.577867 
UACC812 0.536555 0.539204 0.535373 0.525882 Luminal B 0.539204 
UACC893 0.574544 0.579545 0.586481 0.579644 HER2 0.586481 
YMB1 0.536735 0.538636 0.539808 0.533984 HER2 0.539808 
ZR751 0.537049 0.538381 0.537582 0.532485 Luminal B 0.538381 
ZR7530 0.577092 0.579765 0.578823 0.568499 Luminal B 0.579765 
 
 
  
68 
 
Table 7 CCLE cell line FGA values 
Cell line 
Name 
FGA 
Cell line 
Name 
FGA Cell line Name FGA 
CAL851 0.454959 HS578T 0.448292 HCC202 0.640264 
BT549 0.422156 BT20 0.344444 HS739T 0.022813 
EVSAT 0.583262 MDAMB436 0.845678 MDAMB157 0.436991 
MDAMB453 0.3686 MDAMB361 0.546427 MDAMB175VII 0.278391 
HS274T 0.022146 SKBR3 0.574749 HS742T 0.022504 
HS281T 0.023455 HCC1395 0.670912 HS343T 0.022843 
HCC1500 0.774086 HCC1806 0.428133 HCC1954 0.355743 
HCC2157 0.51379 HCC1143 0.470245 HCC2218 0.392192 
HCC1419 0.24137 DU4475 0.252385 CAMA1 0.283514 
BT483 0.361104 HCC70 0.5935 HMC18 0.220312 
ZR7530 0.236611 HCC38 0.645516 YMB1 0.366913 
UACC812 0.446035 ZR751 0.353006 MCF7 0.525897 
HCC1599 0.440108 BT474 0.395631 T47D 0.806502 
JIMT1 0.484 EFM19 0.629806 MDAMB134VI 0.298061 
CAL51 0.024347 MDAMB468 0.694528 KPL1 0.332333 
HDQP1 0.47564 MDAMB231 0.305308 CAL148 0.214785 
CAL120 0.422619 EFM192A 0.5461 UACC893 0.692182 
HMEL 0.057846 HS606T 0.023226 HCC1428 0.467515 
AU565 0.358645 HCC1937 0.487248 HCC1569 0.478483 
MDAMB415 0.535105 HCC1187 0.472756   
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Table 8 CCLE cell line mutation frequencies 
Cell line 
Name 
No. of 
mutation 
No. of base 
pairs 
Mutation 
frequency 
Cell line 
Name 
No. of 
mutation 
No. of 
base pairs 
Mutation 
frequency 
AU565 68 14139745 4.809139 HCC2218 60 13738586 4.367262 
BT20 73 13674648 5.338346 HCC38 45 13065569 3.444167 
BT474 118 13453355 8.771046 HCC70 48 14834814 3.235632 
BT483 58 11819716 4.907055 HMC18 66 12825948 5.145818 
BT549 57 13476716 4.229517 HS281T 31 13729498 2.257912 
CAL120 36 12436514 2.894702 HS343T 29 13775110 2.105246 
CAL148 84 11855608 7.085255 HS578T 40 13580708 2.945355 
CAL51 86 13111361 6.559197 HS739T 45 14655824 3.070452 
CAL851 28 9761310 2.868467 HS742T 27 15306548 1.763951 
CAMA1 67 13179068 5.083819 JIMT1 35 11903158 2.940396 
DU4475 51 11691745 4.362052 KPL1 43 13206920 3.255869 
EFM19 43 13999889 3.071453 MCF7 34 9688929 3.50916 
EFM192A 33 12968331 2.544661 MDAMB134VI 35 14115109 2.479612 
EVSAT 85 13226558 6.426464 MDAMB231 61 13146670 4.639958 
HCC1143 59 13833410 4.265037 MDAMB361 126 14146129 8.90703 
HCC1187 41 13231558 3.098652 MDAMB415 63 10110941 6.230874 
HCC1395 69 13523808 5.102113 MDAMB436 54 11704866 4.613466 
HCC1419 41 11350180 3.612278 MDAMB453 106 12747117 8.315606 
HCC1428 55 10331529 5.32351 MDAMB468 59 11164856 5.284439 
HCC1500 45 11496602 3.9142 SKBR3 63 14593061 4.31712 
HCC1569 180 11367730 15.8343 T47D 34 14832063 2.292331 
HCC1599 50 10634068 4.70187 UACC812 64 14222633 4.49987 
HCC1806 44 13544676 3.248509 UACC893 46 11672003 3.941055 
HCC1954 65 12945787 5.020938 ZR751 20 14639370 1.366179 
HCC202 73 12485249 5.8469 ZR7530 71 14270318 4.975362 
HCC2157 58 13012549 4.457236     
 
 
 
Aniruddha Pawar 
532 Drake Street, Indianapolis, IN 46202 
Phone (317) 559 5454, Email: apawar@iupui.edu 
 
OBJECTIVE 
Seeking a full time opportunity in Bioinformatics where my skills can be utilized to make data 
driven decisions to solve biological problems and deliver optimized solutions 
 
QUALIFICATION HIGHLIGHTS  
 Proficient in microarray, NGS and large multi-omics data analysis 
 Strong proficiency in Perl, Python and R , familiarity with SQL, PHP 
 Experience with UNIX clusters – PBS torque 
 In-depth knowledge of computational and as well as biological concepts 
 Experience of working efficiently on multiple collaborative projects 
 Good communication skills and a team player 
 
WORK EXPERIENCE  
Data analyst – (CCBB), IU School of Medicine                  
October 2012 – Present  
Model cell-lines for testing anti-cancer drugs 
 Identify the cancer cell-lines most similar to breast cancer tissues in patients 
 Characterize critical features such as copy number, gene expression and gene 
mutation in tissue samples and cancer cell-lines and then measure the similarities 
between these features 
 Compute measures of similarities such as correlations between cancer cell-lines and 
cancerous tissues from patients 
Next Generation Sequencing – Identification of excess variants from whole-exome 
sequencing  
 Investigated the genetic variants in two traits of Alzheimer disease using NGS data 
 Annotated variants using ANNOVAR from sequencing data of the participants  
 Identified significant variants using SKAT package in R 
Relationship between age/gender and expression of ‘pharmaco-genes’  
 Detected and reported relationships between several pharmaco-genes and age, 
gender which indicated that age and gender should be taken into account while 
determining the dosage of certain drugs 
 Analyzed microarray data from a liver cohort study to detect these associations 
 Processed the raw microarray dataset to restructure and normalize it  
 
 
 
 
 
Analyst – Symphony Teleca Corporation, India                     
June 2011 to July 2012 
 Worked in a team to build a unified support system for various open source 
bioinformatics tools  
 Explored various open source and licensed biological software tools used for tasks 
such as genome annotation, format conversion, and variant analysis 
 Prepared educational course ware documents to facilitate use and application of 
Bioinformatics software 
 
Graduate research assistant – National Chemical Laboratory (NCL) Pune, India 
(Council of Scientific & Industrial Research, CSIR Lab) February 2011 – May 2011  
 Screened and partially purified extracellular nuclease enzyme from Streptomyces 
aureofaciens (NCIM-2614)  
 
 
EDUCATION 
 Master of Science in Bioinformatics, GPA – 3.95/4.00 
Indiana University, School of Informatics, Indianapolis – May 2015 
 
 Master of Science in Biotechnology 
University of Pune, Pune, INDIA – May 2011 
 
 Bachelor of Science in Biotechnology 
University of Pune, Pune, INDIA – May 2009 
 
TECHNICAL SKILLS 
 Programming languages: Perl, Python, R, SQL, PHP, HTML 
 Databases: MySQL 
 Tools: SVN, GitHub 
 Microarray analysis: Normalization, MeV 
 NGS tools: BWA, Bowtie, SAM tools, VCF tools, GATK, ANNOVAR 
 Public Databases:1000 Genomes, TCGA, NCBI, KEGG, PDB, Gene Expression 
Omnibus (GEO), UCSC genome browser, Cancer Cell Line Encyclopedia (CCLE) 
 Statistical knowledge: Descriptive statistics, hypothesis testing, regression, ANOVA, 
clustering 
 Operating Systems: Windows, Unix/Linux and Macintosh 
 
 
